NEW YORK (GenomeWeb News) – VolitionRx said today it has reached a deal with Active Motif to co-exclusively distribute VolitionRx's NuQ product line in Europe, the US, and Japan.

The NuQ products are based on VolitonRx's Nucleosomics platform for identifying and quantifying nucleosome structural features, such as histone modifications and variations, DNA methylation patterns, and nucleosome-protein adducts.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.